Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

How CJC-1295 Works

CJC-1295 signals the pituitary to release growth hormone, while its studied albumin-binding design extends exposure for days.

Why we wrote this. Mechanism claims are often used as proof of benefits. This separates the measured hormone signal from clinical outcomes.

In this article (5 sections)
  1. Step one: it copies a natural signal
  2. Step two: the pituitary releases more growth hormone
  3. Step three: albumin binding extends exposure
  4. What the mechanism does not prove
  5. What we do not yet know

CJC-1295 is a laboratory-made analogue of growth-hormone-releasing hormone, usually shortened to GHRH. It does not supply growth hormone directly. In the published human studies, it signalled the pituitary gland to release more of the body's own growth hormone, which was followed by higher insulin-like growth factor 1 (IGF-1)[1]. The best-studied molecule also carried an albumin-binding chemical group that kept it in circulation for days[2].

That is the mechanism in plain English: it presses an existing hormonal signal rather than replacing the hormone itself. The distinction matters because online products called CJC-1295 do not always identify whether they contain the long-acting albumin-binding molecule studied in people.

Step one: it copies a natural signal

The hypothalamus, a region of the brain involved in hormone control, normally releases GHRH. GHRH travels to the pituitary and binds the GHRH receptor on somatotrophs, the pituitary cells that make growth hormone. The original development paper describes CJC-1295 as a modified form of the first 29 amino acids of human growth-hormone-releasing factor. In cultured rat pituitary cells and living rats, the molecule activated that same signalling route[2].

A receptor is a protein that receives a chemical signal. Binding does not guarantee a clinical benefit. It starts a chain of cell activity that can change hormone release. The early CJC-1295 programme measured that biological response, not better recovery, more muscle, improved sleep, or longer life.

Step two: the pituitary releases more growth hormone

In two randomized, placebo-controlled ascending-dose studies in healthy adults, one administration of long-acting CJC-1295 raised mean growth-hormone concentrations by twofold to tenfold for at least six days. Mean IGF-1 rose by 1.5-fold to threefold for 9 to 11 days. The investigators estimated a half-life of 5.8 to 8.1 days[1]. Half-life is the time required for the measured amount of a substance to fall by roughly half.

A second human study sampled blood every 20 minutes overnight before and one week after one CJC-1295 administration. Growth-hormone pulses still occurred, but the trough level between pulses rose 7.5-fold. Mean growth hormone rose 46%, and IGF-1 rose 45%[3]. So the phrase 'preserves natural pulses' is incomplete. Pulses persisted on top of a higher baseline in this small physiology experiment.

Step three: albumin binding extends exposure

The defining feature of the studied CJC-1295 was a reactive chemical group designed to attach to cysteine 34 on serum albumin, a long-lived protein in blood. The 2005 development paper found the selected compound in rat plasma beyond 72 hours and detected it at the albumin band on a laboratory blot[2]. The later human study then measured the multi-day half-life[1].

This is why the label 'without DAC' cannot be treated as a minor packaging choice. Anti-doping researchers list CJC-1295 and CJC-1295 with drug affinity complex as separate analytical targets[4]. That paper supports a molecule-identity distinction, not a human half-life for no-DAC material. Our with-DAC versus without-DAC guide explains the naming problem.

What the mechanism does not prove

Higher growth hormone and IGF-1 are laboratory findings. They do not by themselves establish that CJC-1295 treats a disease, improves body composition, speeds injury recovery, or extends life. The main trials were short and enrolled healthy adults. They were designed around pharmacokinetics and hormone concentrations, not patient-centred clinical outcomes.

This also separates CJC-1295 from growth-hormone secretagogues such as ipamorelin. Those compounds act through a different receptor even though both routes can increase growth-hormone release. The distinction is covered on our ipamorelin reference page. Putting two compounds in one vial does not create human evidence for the combination or make their effects interchangeable.

Readers who see historical dose figures should use our human-study dosing explainer. It reports the trial context without converting it into a protocol. The CJC-1295 safety overview also explains why reactions to combination products cannot be assigned cleanly to one ingredient.

What we do not yet know

The public human evidence does not establish a therapeutic indication, a long-term benefit, or long-term safety. It does not establish that products sold under the same name contain the albumin-binding molecule used in the trials. It also does not allow the long-acting pharmacokinetic results to be assigned to no-DAC material or to blends with ipamorelin.

Researchers would need larger controlled trials with a defined product, a target medical condition, and outcomes that matter to patients. They would also need enough follow-up to detect less common harms. Until that work exists, receptor biology and hormone curves remain early evidence rather than a treatment case.

A later programme would also have to decide whether it is testing the long-acting albumin-binding molecule from the early papers, a shorter analogue, or a combination product, because pooling those materials under one familiar name would make even a large trial difficult to interpret and impossible to apply cleanly to a different formulation.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Does CJC-1295 contain growth hormone?

No. It is a GHRH analogue that signals the pituitary gland to release more of the body's own growth hormone.

Why does studied CJC-1295 last for days?

The molecule tested in the main human programme had a reactive group designed to bind serum albumin. The study estimated a half-life of 5.8 to 8.1 days.

Does CJC-1295 stop natural growth-hormone pulses?

A small human physiology study found that pulses persisted, but trough growth hormone rose markedly. Preserved pulses did not mean an unchanged hormone profile.

Does the mechanism prove muscle or fat-loss benefits?

No. The human studies measured pharmacokinetics, growth hormone, and IGF-1. Those endpoints do not by themselves establish a clinical benefit.

Sources

  1. [1]Teichman et al. (2006): Long-acting CJC-1295 in healthy adults (PMID 16352683)Tier 1 · primary↩
  2. [2]Jette et al. (2005): Identification and albumin binding of CJC-1295 (PMID 15817669)Tier 1 · primary↩
  3. [3]Ionescu and Frohman (2006): Growth-hormone pulsatility after CJC-1295 (PMID 17018654)Tier 1 · primary↩
  4. [4]Memdouh et al. (2021): Detection of CJC-1295 analogues (PMID 34665524)Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars